Gastric carcinogenesis;Carcinogénesis gástrica

Revista Colombiana de Gastroenterologia

Volumn 24, Issue 3, 2009, Pages 314-329

  Otero Regino, William ^a   Gómez, Martín A ^a   Castro, Denny ^b  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b Centro de Control de Cáncer Dr Luis E Anderson   (Venezuela)

Author keywords

Carcinogenesis; Helicobacter pylori; Polymorphisms; Stem cell

Indexed keywords

EID: 77952867928     PISSN: 01209957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (162)

1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, versión 2.0 IARC CancerBase No 5 Lyon: IARC 2004.
2. Parkin DM, Bray F, Ferlay J, Paisani P. Global Cancer Statistics 2005; CA Cancer J Clin 2005; 55: 74-108.
3. Krew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-62.
4. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito Sobue T. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008; 38: 259-67.
5. Piñeros M, Hernández G, Bray F. Increasing mortality rates of common malignancies in Colombia. Cancer 2004; 101: 2285-92.
6. Correa P, Piazzuelo MB, Camargo MC. Overview and pathology of gastric cancer. En Wang T, Fox J, Giraud A. (Edit). The biology of gastric cancers. Springer Science Business + Media 2009. p. 21-44.
7. Smith MG, Hold GL, Tahara E, El-Omar EM. Cellular and molecular aspects of gastric cancer. World J Gastroenterol 2006; 12: 2979-90.
8. Mosss SF, Malfertheiner P. Helicobacter and gastric malignancies. Helicobacter 2007; 12(Suppl 1): 23-30.
9. Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology 2005; 128: 1579-1605.
10. Jarvi O, Lauren P. On the role of heterotopias of the intestinal epithelium in the pathogenesis of gastric cancer. Acta Pathol Microbiol Scand 1951; 29: 26-44.
11. Lauren, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
12. Correa P, Carneiro F. Classification of gastric carcinomas. Curr Diagn Pathol 1997; 4: 51-9.
13. Ekstrom AM, Serafini M, Nyren O, Hansson LE, Ye W, Wolk A. Dietary antioxidante intake and the risk of noncardia cancer for the intestinal and diffuse types: a population-based case-control study in Sweden. Int J Cancer 2000; 87: 133-40.
14. El-Omar EM, Lochhead P. Gastric cancer. Br Med Bull 2008; 85: 87-100.
15. Henson DE, Dittus C, Younes M, Nagyen H, AlboresSaavedra J. Differential trends in the intestinal and diffuse topless of gastric carcinoma in the United States-2000: increase in the signet ring cell type. Arch Pathol Lab Med 2004; 128: 765-70.
16. Oliveira C, Seruca R, Carneiro F. Hereditary gastric cancer. Best Pract Res Clin Gastroenterol 2009; 23: 147-57.
17. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003; 14 (suppl 2): ii31-ii36.
18. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-5.
19. Carneiro F, Sobrinho-Simoes M. Hereditary diffuse gastric cancer: lessons from histopatholgy. Adv Anat Pathol 2005; 12: 151-2.
20. Medina-Franco H, Barreto-Zúñiga R, García-Álvarez MN. Preemptive total gastrectomy for hereditary gastric cancer. J Gastrointest Surg 2007; 11: 314-7.
21. Medina-Franco H, Medina AR, Vizcaíno G, Medina-Franco JL. Single nucleotide polymorphisms in the promoter region of the E-cadherin gene in gastric cancer: case-control study in a young Mexican population. Ann Surg Oncol 2007; 14: 2246-9.
22. Cisco RM, Ford JM, Norton JA. Hereditary diffuse gastric cancer. Cancer 2008; 113 (7 Suppl): 1850-6.
23. Masciari S, Larsson N, Senz J, Boid N, Kaurah P, Kandel MJ, et al. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 2007; 44: 726-31.
24. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19 (Suppl.1): S37-S43.
25. Kabir S. Effect of Helicobacter pylori eradication on incident of gastric cancer in human and animal models: underlying biochemical and molecular events. Helicobacter 2009; 14: 159-71.
26. Correa P, Chen VW. Gastric Cancer. Cancer Surv 1994; 19: 55-76.
27. Kono S, Irohata T. Nutrition and stomach cancer. Cancer Causes Control 1996; 7: 41-55.
28. Larsson SC, Bergkvist L, Wolk A. Fruit and vegetable consumption and incidence of gastric cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1998-2001.
29. Bae JM, Lee EJ, Guyatt G. Citrus fruit intake and stomach cancer risk: a quantitative systematic review. Gastric Cancer 2008; 11: 23-37.
30. González CA, Pera G, Agudo A, Buenode Mezquita HB, Ceroti M, et al. Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC- Eurogast). Int J Cancer 2006; 118: 2559-66.
31. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database of Systematic Reviews 2004; Issue 4.
32. Liu C, Huang XD, Russell RM. Diet and gastric cancer. En Wang TC, Fox J, Giraud A. (Edits). The biology of gastric cancers. Springer Science +Business Media LLC 2009. p. 59-89.
33. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 1881-8.
34. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005; 54: 1536-40.
35. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, et al. Nutrition inter vention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483-92.
36. Goswami UC, Sharma N. Efficiency of a few retinoids and carotenoids in vivo in controlling benzo[a]pyrene-induced forestomach tumour in female Swiss mice. Br J Nutr 2005; 94: 540-3.
37. Velmurugan B, Bhuvaneswari V, Burra UK, Nagini S. Prevention of N-methyl-N′-nitro-N-nitrosoguanidine and saturated sodium chloride-induced gastric carcinogenesis in Wistar rats by lycopene. Eur J Cancer Prev 2002; 11: 19-26.
38. Velmurugan B, Bhuvaneswari V, Nagini S. Antiperoxidative effects of lycopene during N-methyl-N′-nitro-N- nitrosoguanidine-induced gastric carcinogenesis. Fitoterapia 2002; 73: 604-11.
39. Velmurugan B, Mani A, Nagini S. Combination of S-allylcysteine and lycopene induces apoptosis by modula- ting Bcl-2, Bax, Bim and caspases during experimental gas- tric carcinogenesis. Eur J Cancer Prev 2005; 14: 387-93.
40. Liu C, Russell RM, Wang XD. Lycopene supplementation prevents smoke-induced changes in p53, p53 phosphoryla- tion, cell proliferation, and apoptosis in the gastric mucosa of ferrets. J Nutr 2006; 136: 106-11.
41. Wang X, Willen R, Wadstrom T. Astaxanthin-rich algal meal and vitamin C inhibit Helicobacter pylori infection in BALB/ cA mice. Antimicrob Agents Chemother 2000; 44: 2452-7.
42. Liu BH, Lee YK. Effect of total secondary carotenoids extracts from Chlorococcum sp on Helicobacter pylori-infected BALB/c mice. Int Immunopharmacol 2003; 3: 979-86.
43. World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. Washington, DC: American Institute for cancer Research 1997.
44. Kato S, Tsukamoto T, Mizoshita T, Tanaka H, Kumagai T, Ota H, Katsuyama T, Asaka M, Tatematsu M. High salt diets dose-dependently promote gastric chemical carcinogenesis in Helicobacter pylori-infected Mongolian gerbils associated with a shift in mucin production from glandular to surface mucous cells. Int J Cancer 2006; 119: 1558-66.
45. Watanabe H, Takahashi T, Okamoto T, Ogundigie PO, Ito A. Effects of sodium chloride and ethanol on stomach tumorigenesis in ACI rats treated with N-methyl-N′-nitro- Nnitrosoguanidine: a quantitative morphometric approach. Jpn J Cancer Res 1992; 83: 588-93.
46. Furihata C, Sato Y, Hosaka M, Matsushima T, Furukawa F, Takahashi M. NaCl induced ornithine decarboxylase and DNA synthesis in rat stomach mucosa. Biochem Biophys Res Commun 1984; 121: 1027-32.
47. Sorbye H, Kvinnsland S, Svanes K. Effect of salt-induced mucosal damage and healing on penetration of N-methyl- N′-nitro-N-nitrosoguanidine to proliferative cells in the gas- tric mucosa of rats. Carcinogenesis 1994; 15: 673-9.
48. Fox JG, Dangler CA, Taylor NS, King A, Koh TJ, Wang TC. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res 1999; 59: 4823-8.
49. Jakszyn P, González, CA. Nitrosamine and related food intake and gastric and oesophageal cancer risk: a syste- matic review of the epidemiological evidence. World J Gastroenterol 2006; 12: 4296-303.
50. Mirvish SS. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyn- geal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett.1995; 93: 17-48.
51. Jakszyn P, Bingham S, Pera G, Agudo A, Luben R, Welch A, et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC- EURGAST) study. Carcinogenesis.2006; 27: 1497-501.
52. Schistosomes, Liver fluyes and Helicobacter pylori IARC Working group on the evaluation of carcinogenic risks to humans. Lyon, 7-14 June 1994. IARC Monog Eval Carcinog Risks Hum 1994; 61: 1-41.
53. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991, 302: 1302-5.
54. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentrich N, et al. Helicobacter pylori infec- tion and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-31.
55. Nomura A, Stemmermann GN, Chyou PH, Kato I, PerezPerez GI, Blaser M, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325: 1132-6.
56. Sugiyama A, Maruta F, Ikeno T, Ishida K, Kawasaki S, Katsuyama T, et al. Helicobacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil. Cancer Res 1998; 58: 2067-69.
57. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology 1998; 115: 642-8.
58. An International association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 1993; 341: 1359-62.
59. Huang JQ, Zheng GF, Sumanak K, Irvine EJ, Hunt RH. Metaanalysis of the relationship between cag A seropositivity and gastric cancer. Gastroenterology 2003; 125: 1636-44.
60. Peter S, Begglinnger C. Helicobacter pylori and gastric cancer: The causal relationship. Digestion 2007; 75: 25-35.
61. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.
62. Mueller A, Falkow S, Amieva MR. Helicobacter pylori and gastric cancer: what can be learned by studying the response of gastric epithelial cells to the infection? Cancer Epidemiol Biomarkers Prev 2005; 14: 1859-64.
63. Peter S, Beglinger C. Helicobacter pylori and gastric cancer: the causal relationship. Digestion 2007; 75: 25-35.
64. Wu MS, Shun CT, Wu CC, et al. Epstein Barr virus associated with Helicobacter pylori. Infection and genetic alterations. Gastroenterology 2000; 118: 1031-8.
65. Report of the Digestive Health Initiative International Update. Conference on Helicobacter pylori. Gastroenterology 1997; 113 (Suppl): S4-S8.
66. Saad R, Chey W. A clinician's guide to managing Helicobacter pylori infection. Clev Clin J Med 2005; 72: 109-124.
67. Parsonnet J. Helicobacter pylori: the size of the problem. Gut 1998; 43: S6-S9.
68. Correa P, Schneider BG. Etiology of gastric cancer: what is new? Cancer Epidemiol Biomarkers Prev 2005; 14: 1865-8.
69. Guillen D, McColl KEL. Gastroduodenal disease, Helicobacter pylori, and genetic polymorphisms. Clinical Gastroenterol Hepatol 2005; 3: 1180-86.
70. El Omar EM, Penman I, Ardill JE, Chittajallu RS, Howie C, Mc Coll KE, et al. Helicobacter pylori infection and abnor- malities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109:681-91.
71. Lai LH, Sung JJY. Helicobacter pylori and benign upper digestive disease. Best Pract Res Clin Gastroenterol 2007; 21: 261-79.
72. Faber K. Chronic gastritis: its relation to achylia and ulcer. Lancet 1927; 2: 902-7.
73. Graham DY, Lu H, Yamaoka Y. African, Asian or Indian enigma, the East Asian Helicobacter pylori: facts or medical myths. J Dig Dis 2009; 10: 77-84.
74. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
75. Chiba T, Seno H, Marusawa Y, Okazaki K. Host factors are important in determining clinical outcomes of Helicobacter pylori infection. J Gastroenterol 2006; 41: 1-9.
76. Chiba T, Marusawa H, Seno H, Watanabe N. Mechanism Fort he gastric cancer development by Helicobacter infection. J Gastroenterol Hepatol 2008; 23: 1175-81.
77. Bonnevie O. The incidence of duodenal ulcer in Copenhagen County. Gastroenterology 1975; 10: 385-93.
78. Hu PJ, Li YY, Zhou MH, Chen MH, Huang BJ, Mitchel HM, et al. Helicobacter pylori associated with a high prevalence of duodenal ulcer disease and low prevalence of gastric cancer in a developing nation. Gut 1995; 36: 198-202.
79. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg pathol 1995; 19: S37-S43.
80. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori Basic research to patient care. Gastroenterology 2006; 130: 188-206.
81. Matsukura N, Suzuki K, Kavachi T, Aoyagi M, Sugimura T, Kitaoka H, et al. Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. J Natl Cancer Inst 1980; 65: 231-40.
82. Correa P, Hoghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007; 133: 659-72.
83. Farinati F, Cardin R, Cassaro M, Bortolami M, Nitti D, Tieppo, et al. Helicobacter pylori, inflammation, oxidative damage and gastric cancer: a morphological, biological and molecular pathway. Eur J Cancer Prev 2008; 17: 195-200.
84. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T. Helicobacter pylori infection triggers aberrant expresión of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007; 13: 470-6.
85. Takaishi S, Wang TC. Providing AID to p53 mutagenesis. Nat Med 2007; 13: 404-6.
86. Correa P, Haenszel W, Cuello C, Tannembaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975; 2: 58-60.
87. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-5.
88. Correa P. The epidemiology and pathogenesis of chronic: three etiologic entities. Front Gastrointest Res 1980; 6: 98-108.
89. Correa P. Clinical implications of recent development in gastric cancer pathology and epidemiology. Sem Oncol 1985; 12: 2-10.
90. Bonne C, Hartz PH, Klerks JV, Posthuma JH, Radsma W, Tjokronegoro S, et al. Morphology of the stomach and gas- tric secretion in Malays and Chinese and the different incident of gastric ulcer and cancer in these races. Am J Cancer 1938; 33: 265-79.
91. Siurala M, Varis K, Wiljasalo M. Studies of patients with atrophic gastritis: a 10 -15 year follow-up. Scand J Gastroenterol 1966; 1: 40-8.
92. Volk J, Parsonnet J. Epidemiology of Gastric Cancer. En Wang TC, Fox J, Giraud A. (Eds). The biology of Gastric cancers. Springer Science + Business Media LLC 2009. p. 25-57.
93. Matysiak-Budnik T, Mégraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer 2006; 42: 708-16.
94. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, Viala J, et al. NodI detect a unique muropeptide from gram negative bacterial peptidoglycan. Science 2003; 300: 1584-87.
95. Girardin SE Travassos LH, Herve M, Blanot D, Boneca IG, Philpott DJ, et al. Peptiglycan molecular requeriments allowing detection by NodI and Nod2. J Biol Chem 2003; 278: 41702-8.
96. Keeffe J, Moran AP. Conventional, regulatory and unconventional T cells in the immunologic response to Helicobacter pylori. Helicobacter 2008; 13: 1-19.
97. Ma J, Chen T, Mandelin J, Ceponis A, Miller NE. Regulation of macrophage activation. Cell Mol Life Sci 2003; 60: 2334-46.
98. Malaty HM. Epidemiology of Helicobacter pylori. Best Pract Res Clin Gastroenterol 2007; 21: 205-14
99. Hold G, Rabkin CS, Chow WH, Smith MG, Gammon MD, Sisch HA, et al. A gunctional polymorphisms of Toll like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007; 132: 905-12.
100. Hisida A, Matsuo K, Goto Y, Mitsuda Y, Hiraki K, Naito M, et al. Toll-like Receptor 4+3725G/C polymorphisms, Helicobacter pylori seropositivity and the risk of gastric atrophy and gastric cancer. Helicobacter 2009; 14: 47-53.
101. D'Elios MM, Amedi A, Benagiano M, Azzurri A, Del Prete G. Helicobacter pylori, T cells and cytokines: the dangerous liaisons. FEMS Immunol Med Microbiol 2005; 44: 113-9.
102. Lehmann FS, Terracciano L, Carena I, Baeriswyl C, Drewe J, Tornillo L, et al. In situ correlation of cytokine secretion and apoptosis in Helicobacter pylori-associated gastritis. Am J Physiol Gastrointest Liver Physiol 2002; 283: G481-G488.
103. Holcombe C. Helicobacter pylori: The African enigma. Gut 1992; 33: 429-31.
104. Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, et al. The prevalence of Th17 cells in patients with gastric cáncer. Bioch Bioph Res Com 2008; 374: 533-7.
105. Argent RH, Kidd M, Owen RJ, Thomas RJ, Limb MC, Atherton JC. Determinants and consequences of different levels of Cag A phosphorilation for clinical aislates of Helicobacter pylori. Gastroenterology 2004; 127: 514-23.
106. Farinati F, Cardin R, Cassaro M, Bortolami M, Nitti D, Tieppo C, et al. Helicobacter pylori, inflammation, oxidative damage and gastric cancer: morphological, biological and molecular pathway. Eur J Cancer Prev 2008; 17: 95-200.
107. Wu MS, Chen CJ, Lin JT. Host environment interactions: their impact on progression from gastric inflammation to carcinogenesis and the development to new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1878-82.
108. Amieva MR, El-Omar EM. Host bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134: 306-23.
109. Ferreira AC, Isomoto H, Moriyama M, Fujioka T, Machado JC, Yamaoka Y. Helicobacter and gastric malignancies. Helicobacter 2008; 13 (Suppl 1): 28-34.
110. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004; 113: 321-33.
111. Wallace JL, Cucala M, Mugridge K, Parente L. Secretagoguespecific effects of interleukin-1 on gastric acid secretion. Am J Physiol 1991; 261: G559-64.
112. El-Omar EM, Carrington M, Chow WH, McColl KEL, Bream JH, Young HA, et al. Interleukin-1 plymorphims associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
113. Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figuereido C, et al. Interleukin-1b and interleukin-1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001; 121: 823-9.
114. Chen A, Li CN, Hsu PI, Lai KH, Tseng HH, Hsu PN, et al. Risks of interleukin-1 genetic polymorphisms and Helicobacter pylori infection in the development of gastric cancer. Aliment Pharmacol Ther 2004; 20: 203-11.
115. Lahner E, Corleto VD, D'Ambra G, Di Giulio E, D'Elle Fave G, Anibale B. Is Interleukin 1 genotyping useful for the clinical management of patients with atrophic body gastritis? Aliment Phrmacol ther 2008; 27: 355-65.
116. Palli D, Saieva C, Luzzi I, Masala G, Topa S, Sera F, et al. Interleukin- 1 gene polymorphisms and gastric cancer risk in a high-risk Italian population. Am J Gastroenterol 2005; 100: 1941-8.
117. Lee SG, Kim B, Choi W, Lee I, Choi J, Song K. Lack of association between pro-inflammatory genotypes of the interleukin-1 (IL-1B -31 C/+ and IL-1RN *2/*2) and gastric cancer/duodenal ulcer in Korean population. Cytokine 2003; 21: 167-71.
118. Wang P, Xia HH, Zhang JY, Dai LP, Xu XQ, Wang KJ. Association of interleukin-1 gene polymorphisms with gastric cancer: a meta-analysis. Int J cancer 2007; 120: 552-62.
119. Camargo MC, Mera R, Correa P, Peek Jr RM, Fontham ET, Goodman KJ, et al. Interlukin-1beta and antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1674-87.
120. Kamangar F, Cheng C, Abnet CC, Rabkin C. Interleukin -1B polymorphisms and gastric cancer risk-A Metanalysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1920-8.
121. Meining A, Morgner A, Miehlke S, Morgner A, Bayerdorffer E, Stolte M. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely a hypothesis? Best Pract Res Gastroenterol 2001; 15: 983-98.
122. Filipe MI, Muñoz N, Matko I, Kato I, Pompe-Kim V, Jutersek A, et al. Intestinal metaplasia types and the risk of gastric cancer: A cohort in Slovenia. Int J Cancer 1994; 57: 324-9.
123. Ectors N, Dixon MF. The pronostic value of sulphomucin positive intestinal metaplasia in the deveopment of gastric cancer. Histopahology 1986; 10: 1271-7.
124. El Zimaity HM, Ramchatesingh J, Saeed MA, Hraham DY. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol 2001; 54: 679-83.
125. Kakinoki R, Kushima R, Matsubara A, Saito Y, Okabe H, Fujiyama Y et al. Re-evaluation of histogenesis of gastric carcinoma: A comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases. Dig Dis Sci 2009; 54: 614-20.
126. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. Gastric cancer originating from bone marrowderived cells. Science 2004; 306: 1568-71.
127. Li HC, Stoicov C, Rogers AB, Houghton J. Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers. World J Gastroenterol 2006; 12: 363-71.
128. Houghton J, Morozov A, Smirnova I, Wang TC. Stem Cell and Cancer. Seminars Cancer Biol 2007; 17: 191-203.
129. Takaishi S, Okumura T, Wang TC. Gastric cancer Stem Cell. J Clin Oncol 2008; 26: 2876-82.
130. Azuma T. Role of Cag A in the Helicobacter pylori infection and pathology. En Wang TC, (Eds). The biology of gastric cancers. Springer Science+Business Media, LLC 2009. p. 389-401.
131. Harcker J, Kaper JB. Pathogenicity Islands and the Evolution of Microbes. Ann Rev Microbiol 2000; 54: 641-679.
132. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, et al. Cag A pathogenicity islad of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U.S.A 1996; 93: 14648-53.
133. Crowe SE. Helicobacter pylori infection, chronic inflammation and the development of malignancy. Curr Op Gastroenterol 2005; 21: 32-38.
134. Backert S, Selbach M. Role of type IV secretion in Helicobacter pylori pathogenesis. Cel Microbiol 2008; 10: 1573-81.
135. Handa O, Naito Y, Yoshikawa T. CagA protein of Helicobacter pylori: A hijacker of gastric epithelial cell signalin. Bioch Pharmacol 2007; 73: 1697-1702.
136. Suzuki M, Mimuro H, Kiga K, Fukumatsu M, Ishijima N, Morikawa H, et al. Helicobacter pylori CagA Phosphorylation-Independent function in epithelial proliferation and inflammation. Cell Host Micr 2009; 5: 23-34.
137. Steffen Backert and Matthias Selbach. Role of type IV secretion in Helicobacter pylori pathogenesis. Cel Microbiol 2008; 10: 8: 1573-1581.
138. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004; 4: 688-94.
139. Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natnl Acad Sci 2008; 105: 1003-8.
140. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer can be explained by differences between Helicobacter pylori Straits. Intern Med 2008; 47: 1077-83.
141. Fox JG, Wang TC. Inflammation atrophy and gastric cancer. J Clin Invest 2007; 17: 60-9.
142. Cover TL, Tummuru MKR, Cao P, Thompson SA, Blaser MJ. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori Straits. J Biol Chem 1994; 269: 1566-573.
143. Yuan JP, Li T, Chen HB, Li ZH, Yang GZ, Hu BH, et al. Analysis of gene expression profi le in gastric cancer cells stimulated with Helicobacter pylori isogenic strains. J Med Microbiol 2004; 53: 965-74.
144. Atherton JC, Cao P, Peek RM Jr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori peptic ulceration. J Biol Chem 1995; 270: 1771-7.
145. Sugimoto M, Yamaoka Y. The association of vacA genotype and Helicobacter pylori-related disease in Latin American and African populations. Clin Microbiol Infet 2009 Early Rel (acceso junio 10, 2009).
146. Letley DP, Atherton JC. Natural Diversity in the n terminus of the mature vacuolating cytotoxin of Helicobacter pylori determines cytotoxin activity. J Bacteriol 2000; 182: 3278-80.
147. Rhead JL, Letley DP, Mohammadi M, Hussein N, Mohagheghi MA, Eshagh M, et al. A new Helicobacter pylori Vacuolating cytotoxin determinant the intermediate region is associated with gastric cancer. Gastroenterology 2007; 133: 926-36.
148. Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, et al. Helicobacter pylori adhesion binding fucosylated histo-blood group antigens revealed by retagging. Science 1998; 279: 373-7.
149. Peek Jr RM, Thompson SA, Donahue JP, Tham KT, Athertton JC, Blaser MJ, et al. Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene ice A, that is associated with clinical outcome. Proc Assoc Am Phys 1998; 110: 531-44.
150. Yamaoka Y, Kudo T, Lu H, Casola A, Brasier AR, Graham DY. Role of interferon-stimulated responsiveelement-like element in inteleukin8 promoter in Helicobacter pylori infection. Gastroenterology 2004; 126: 1030-45.
151. Yamaoka Y, Kwon DH, Graham DY, A M (r). 34 000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci USA 2000; 97: 7533-8.
152. Kontouras J, Zavos C, Chatzopoulos D, Katsinelos P. New aspects of Helicobacter pylori infection involvement in gastric oncogenesis. J Surg Res 2008; 146: 149-58.
153. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-1201.
154. Beales IL, Calam J. Interleukin 1 beta and tumor necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 1998; 42: 227-34.
155. Lu W, Pan K, Zhang L, Lin D, Miao X, You W. Genetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor (alpha) and risk of gastric cancer in a Chinese population. Carcinogenesis 2005; 26: 631-6.
156. Ohyauchi M, Imatani A, Yonechi M, Asano N, Miura A, Lijima K, et al. The polymorphisms inerleukin 8-251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut 2005; 54: 330-5.
157. Malfertheiner P, Megraud F, ÓMorain C Bazzoli F, El-Omar E, Graham DY, et al. Current concepts in the management of Helicobacter pylori infection- The Maastricht III consensus report. Gut 2007; 56: 772-81.
158. Wong BC, Lam FK, Wong WM, Chen JS, Zheng TT, Fen RE, et al. Helicobacter pylori eradication to prevent gastric cancer in high risk region in China: a randomized controlled trial. JAMA 2004; 291: 187-94.
159. Lochhead P, El-Omar EM. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol 2007; 21: 281-97.
160. De Vries AC, Kuipers EJ, Raws EAJ. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol 2009; 104: 1342-5.
161. Zullo A, Hassan C, Andriani A, Cristoffari F, De Francesco V, Ierardi E, et al. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: A pooled Data Analysis. Am J Gastroenterol 2009 advance online publication 16 june 2009.
162. Malferthteiner P, Schulktze V, Rosenkranz B, Kauffman SHE, Ulrichz T, Novicki D, et al. Safety and inmunogenecity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008; 135: 787-95.